Intradialytic Drug Removal by Short-daily Hemodialysis
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Short-daily hemodialysis is increasingly becoming a preferred alternative to the conventional
intermittent (three times per week) hemodialysis schedule. Studies have shown that
short-daily dialysis improves a patient's quality of life, high blood pressure, anemia and
calcium-phosphorus balance. Infection, however, will likely remain a persistent problem for
dialysis patients regardless of the frequency of treatments. There is currently a wealth of
information to guide doctors on how much and how frequently to give an antibiotic for
patients who receive intermittent (thrice weekly) hemodialysis. However, there is very little
information on how to prescribe antibiotics for patient's receiving short-daily hemodialysis.
This study will develop drug dose guidelines for patients receiving short-daily hemodialysis
for three frequently used antibiotics, vancomycin, levofloxacin and gentamicin. These
guidelines will assist doctors so that patients receive the most effective dose and frequency
of an antibiotic to treat their infection.
The following is the study hypothesis which will be tested with two-sided, one sample t-tests
comparing the AUC observed to historical measures8.
1) Vancomycin, levofloxacin and gentamicin are removed to a greater extent by short-daily
hemodialysis than intermittent hemodialysis.
The following are the specific aims:
1. Determine the interdialytic pharmacokinetics of vancomycin, gentamicin, and levofloxacin
by short-daily HD.
2. Determine the extent of vancomycin removal when administered during the last hour of
short-daily HD.
3. Develop drug-dosing guidelines for vancomycin, gentamicin and levofloxacin for patients
receiving short-daily HD.